Expression of Astrocyte-Related Receptors in Cortical Dysplasia With Intractable Epilepsy

Sayuri Sukigara, MD, Hongmei Dai, MD, PhD, Shin Nabatame, MD, Taisuke Otsuki, MD, PhD, Sae Hanai, MD, Ryoko Honda, MD, Takashi Saito, MD, Eiji Nakagawa, MD, PhD, Takanobu Kaido, MD, PhD, Noriko Sato, MD, PhD, Yuu Kaneko, MD, PhD, Akio Takahashi, MD, PhD, Kenji Sugai, MD, PhD, Yuko Saito, MD, PhD, Masayuki Sasaki, MD, PhD, Yu-ichi Goto, MD, PhD, Schuichi Koizumi, PhD, and Masayuki Itoh, MD, PhD

Abstract

Epilepsy is one of the major neurologic diseases, and astrocytes play important roles in epileptogenesis. To investigate possible roles of astrocyte-related receptors in patients with intractable epilepsy associated with focal cortical dysplasia (FCD) and other conditions, we examined resected epileptic foci from 31 patients, including 23 with FCD type I, IIA, or IIB, 5 with tuberous sclerosis complex, and 3 with low-grade astrocytoma. Control samples were from 21 autopsied brains of patients without epilepsy or neurologic deficits and 5 patients with pathologic gliosis without epilepsy. Immunohistochemical and immunoblot analyses with antibodies against purinergic receptor subtypes P2RY1, P2RY2, P2RY4, potassium channels Kv4.2 and Kir4.1, and metabotropic receptor subtypes mGluR1 and mGluR5 were performed. Anti-glia fibrillary acidic protein, anti-NeuN, and anti-CD68 immunostaining was used to identify astrocytes, neurons, and microglia, respectively. Most glial fibrillary acidic protein-immunopositive astrocyte cells in the brain samples from patients with epilepsy were P2RY1-, P2RY2-, P2RY4-, Kv4.2-, and Kir4.1-, mGluR1-, and mGluR5-positive, whereas samples from controls and pathologic gliosis showed lower expression levels of these astrocyte-related receptors. Our findings suggest that, although these receptors are necessary for astrocyte transmission, formation of the neuron-glia network, and other physiologic functions, overexpression in the brains of patients with intractable epilepsy may be associated with activation of intracellular and glio-neuronal signaling pathways that contribute to epileptogenesis.

Key Words: Astrocyte, Cortical dysplasia, Epilepsy, Metabotropic receptor, Potassium channels, Purinergic receptor.

INTRODUCTION

Epilepsy is one of the major neurologic diseases characterized by recurrent seizures and characteristic psychomotor symptoms (1). The pathophysiology of epilepsy is generally recognized to be caused by abnormal excitation of neurons with spread or synchronization throughout the brain. Many studies have demonstrated physiologic dysfunction and morphologic abnormalities of neurons in the brains of patients with epilepsy. Recently, a significant role for astrocytes in the causation of neuronal firing has been described (2). Epileptic foci are populated by increased numbers of astrocytes, suggesting physiologic roles for glia in epilepsy pathogenesis (2–4). Recent studies demonstrate favorable long-term outcomes in patients with hippocampal sclerosis (5,6) and other types of intractable epilepsy (i.e. focal cortical dysplasia [FCD] and tuberous sclerosis complex [TSC]) after surgical resection of epileptic foci. Resection specimens from these patients facilitate studies of epileptogenesis.

In FCD and TSC, there are balloon cells that have some biologic characteristics of astrocytes but that may have several properties that differ from those in astrocytes in the normal brain. Indeed, astrocytes express various cell surface receptors that are similar to those of neurons (7). These receptors can be activated by synthetically released neurotransmitters, glial transmitters, and other molecules in the extracellular space (8,9). Among the receptors expressed on astrocytes are glutamate receptors and both ionotropic and metabotropic receptors (mGluR) (10). Metabotropic GluR2/3, mGluR4, and mGluR8 are expressed in reactive astrocytes of epileptic
brains, and mGluR1, mGluR5, and mGluR8 are reported to be upregulated in the hippocampus in experimental animal models of temporal lobe epilepsy (11). Activation of these receptors leads to increased intracellular Ca2+ concentrations and wave propagation resulting in the release of glutamate from astrocytes (8,10). Several studies have also demonstrated the presence of voltage-dependent sodium, potassium, and calcium ion channels on astrocytes (12). The inwardly rectifying potassium ion (Kir) channels on astrocytes play a major role in the removal of potassium from the extracellular space (12). In specimens from patients with temporal lobe epilepsy, analysis of the ratio of their inward to outward potassium conductance showed that they were significantly smaller in astrocytes in lesions versus those of nonepileptic areas (13). The Kir 4.1 subunit is involved in this epileptic condition (13,14). Moreover, appreciation of the potential impact of astroglial ATP release on seizure activity is emerging (15).

Purinergic receptors are expressed in various mammalian cells and are activated by extracellular adenine and uridine nucleotides (16). Purinergic type 2 (P2) receptors expressed in brain cells regulate important physiologic functions, including neurotransmission, inflammation, cell growth, and apoptosis (17–19). Recently, the P2 receptor subtype Y1, P2RY1 in astrocytes, was reported to inhibit excitatory glutamatergic synaptic neurotransmission (20). Purinergic type 2 receptors are recognized as important components of glio-neuronal transmission in regulating neuronal excitation (17,18).

To facilitate the development of new treatments for epilepsy, it is important to understand the pathobiologic roles of astrocytes in epileptogenesis. Therefore, we investigated the expression of astrocyte receptors in epileptic lesions.

**MATERIALS AND METHODS**

**Cases**

Thirty-one patients with the diagnoses of FCD (n = 23), TSC (n = 5), or low-grade astrocytoma (LGA) (n = 3) were selected from the registered repository of surgical material at our hospital. The patients were diagnosed as having intractable epilepsy and had had surgical resection of epileptic foci for treatment. For controls, 28 autopsy brain samples from patients without epilepsy or neurologic deficits were used (Table, Supplemental Digital Content 1, http://links.lww.com/NEN/A618). The surgical samples were obtained from epilepticogenic areas, as determined by analysis of seizure semiology, ictal and interictal electroencephalography, and neuroimaging such as magnetic resonance imaging and positron emission tomography. The developmental quotient and intelligence quotient were calculated for each case. The number of double-marked cells was counted from 3 randomly chosen areas of each section, under 100× magnification of a light microscope. The number was corrected per 100 nuclei in each area of each section, under 100× magnification of a light microscope.

**Immunostaining Analysis**

Immunopositive cells were counted, and the ratio of double-immunopositive cell numbers per GFAP-, NeuN- or CD68-positive cell was calculated from 3 randomly chosen areas of each section, under 100× magnification of a light microscope.

**Pathologic Analysis**

All samples had been fixed in 10% buffered formalin or 4% paraformaldehyde and embedded in paraffin. Four- or 6-μm-thick serial sections were cut and stained with hematoxylin and eosin and with Luxol fast blue/cresyl violet (Klüver-Barrera). For immunohistochemistry, sections were deparaffinized with xylene and ethanol and incubated at 90°C for 10 minutes with 0.1% succinate buffer for antigen retrieval. Nonspecific binding of IgG was blocked by incubation with 2% normal goat serum for 30 minutes at room temperature. Sections were then incubated with the primary antibodies overnight at 4°C. The primary antibodies used were polyclonal antibodies to P2RY1 (dilution of 1/100; MBL International Co., Woburn, MA), P2RY2 (1/100; MBL International Co.), P2RY4 (1/100; Acris Antibodies, San Diego, CA), Kv4.2 (1/1000; Abcam, Cambridge, UK), Kir4.1 (1/100; Abcam), mGluR1 (1/50; Abcam), and mGluR5 (1/100; Chemicon International Inc., Billerica, MA). Monoclonal anti–glial fibrillary acidic protein (GFAP) (1/100; Cell Signaling Technology Inc., Beverly, MA) was used as an astrocyte marker; anti-NeuN (1/500; Chemicon International Inc.) was used as a neuron marker; and anti-CD68 (1/50; Chemicon International Inc.) was used as a microglia marker. The sections were then sequentially incubated with the secondary rabbit IgG or mouse IgG antibodies (Nichirei Co., Tokyo, Japan), followed by additional staining with the chromogen 3-amino-9-ethyl carbazole substrate (Nichirei Co.), and counterstained with hematoxylin. For double staining, the secondary antibodies used were a fluorescein isothiocyanate–conjugated chicken anti–rabbit IgG and a tetramethyl rhodamine isothiocyanate–conjugated donkey anti-mouse IgG (Life Technologies Co., Grand Island, NY). The sections were mounted with a 4,6-diamidino-2-phenylindole (Vector Laboratories, Inc., Burlingame, CA) for labeling nuclei. The stained sections were observed with a fluorescent microscope (Olympus Co., Tokyo, Japan).

Immunopositive cells were counted, and the ratio of double-immunopositive cell numbers per GFAP-, NeuN- or CD68-positive cell was calculated from 3 randomly chosen areas of each section, under 100× magnification of a light microscope.

**Astrocyte Receptors in Cortical Dysplasia**

© 2014 American Association of Neuropathologists, Inc.
### TABLE. Patient Data

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age at Onset</th>
<th>Seizure Type</th>
<th>Lesion</th>
<th>EEG</th>
<th>DQ/IQ</th>
<th>Age at Surgery</th>
<th>DQ/IQ*</th>
<th>Engel Score†</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>FCD I</td>
<td>M</td>
<td>3 m</td>
<td>Spasm and tonic seizure</td>
<td>LO-P</td>
<td>Spikes, SW at LO, P</td>
<td>14</td>
<td>1 y 0 m</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>M</td>
<td>3 y 6 m</td>
<td>GTC</td>
<td>RF</td>
<td>Sharp waves, SW at RF</td>
<td>98</td>
<td>4 y 4 m</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>M</td>
<td>3 y 5 m</td>
<td>CPS</td>
<td>RT</td>
<td>Spikes, SW at RT</td>
<td>62</td>
<td>13 y 4 m</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>M</td>
<td>11 y 0 m</td>
<td>CPS and GTC</td>
<td>RT</td>
<td>Spikes at RT</td>
<td>76</td>
<td>13 y 10 m</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>M</td>
<td>20 y</td>
<td>CPS</td>
<td>LT</td>
<td>Spikes at LT</td>
<td>68</td>
<td>43 y 4 m</td>
</tr>
<tr>
<td>6</td>
<td>FCD IIa</td>
<td>M</td>
<td>9 d</td>
<td>Asymmetric tonic spasm</td>
<td>R F</td>
<td>Spikes, SW at RF, C</td>
<td>125</td>
<td>1 m</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>M</td>
<td>1 d</td>
<td>Tonic seizure</td>
<td>L P</td>
<td>Slow waves, sharp, SB at L hemisphere</td>
<td>150</td>
<td>3 m 19 d</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>F</td>
<td>1 m</td>
<td>Tonic seizure</td>
<td>R T</td>
<td>Spikes, SW at R hemisphere</td>
<td>100</td>
<td>3 m 21 d</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>M</td>
<td>6 d</td>
<td>GTC</td>
<td>R O</td>
<td>SW at R hemisphere</td>
<td>175</td>
<td>3 m 22 d</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>M</td>
<td>1 m</td>
<td>Spasm and GTC</td>
<td>L P</td>
<td>Hypsarrhythmia</td>
<td>49</td>
<td>8 m</td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>M</td>
<td>1 m</td>
<td>R Upper limb clonic seizure</td>
<td>R F</td>
<td>Slow waves, spikes at RF</td>
<td>64</td>
<td>9 m</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>F</td>
<td>2 y 1 m</td>
<td>Tonic seizure</td>
<td>R F</td>
<td>Rhythmic fast waves at RF</td>
<td>nd</td>
<td>6 y 4 m</td>
</tr>
<tr>
<td>13</td>
<td>F</td>
<td>F</td>
<td>8 y 3 m</td>
<td>Hypermotor seizure</td>
<td>R T</td>
<td>Spikes at RT</td>
<td>83</td>
<td>8 y 10 m</td>
</tr>
<tr>
<td>14</td>
<td>F</td>
<td>F</td>
<td>1 y 6 m</td>
<td>Hypermotor seizure</td>
<td>R F</td>
<td>Spikes at LF, P</td>
<td>50</td>
<td>11 y 0 m</td>
</tr>
<tr>
<td>15</td>
<td>FCD IIb</td>
<td>M</td>
<td>6 d</td>
<td>Tonic seizure</td>
<td>R O</td>
<td>Slow waves at RO, T, F</td>
<td>78</td>
<td>3 m</td>
</tr>
<tr>
<td>16</td>
<td>F</td>
<td>M</td>
<td>9 m</td>
<td>Tonic seizure</td>
<td>L T</td>
<td>Spikes at LT</td>
<td>64</td>
<td>1 y 8 m</td>
</tr>
<tr>
<td>17</td>
<td>F</td>
<td>M</td>
<td>4 m</td>
<td>Atonic seizure</td>
<td>nd</td>
<td>Rhythmic slow waves at LC, P</td>
<td>100</td>
<td>2 y 2 m</td>
</tr>
<tr>
<td>18</td>
<td>F</td>
<td>F</td>
<td>1 y 0 m</td>
<td>GTC</td>
<td>R F</td>
<td>Slow waves at RF</td>
<td>20</td>
<td>2 y 10 m</td>
</tr>
<tr>
<td>19</td>
<td>F</td>
<td>F</td>
<td>6 y 6 m</td>
<td>R Tonic seizure</td>
<td>L F</td>
<td>Slow waves, sharp, SB at LF, C, P</td>
<td>96</td>
<td>8 y 3 m</td>
</tr>
<tr>
<td>20</td>
<td>F</td>
<td>M</td>
<td>6 y 11 m</td>
<td>R Clonic seizure</td>
<td>L F</td>
<td>Rhythmic slow waves at LF, C, P</td>
<td>76</td>
<td>8 y 3 m</td>
</tr>
<tr>
<td>21</td>
<td>F</td>
<td>M</td>
<td>1 y</td>
<td>CPS</td>
<td>R O</td>
<td>Rhythmic fast waves at RO</td>
<td>68</td>
<td>11 y 0 m</td>
</tr>
<tr>
<td>22</td>
<td>F</td>
<td>M</td>
<td>5 y 11 m</td>
<td>GTC</td>
<td>L F</td>
<td>SW at LF</td>
<td>75</td>
<td>12 y 2 m</td>
</tr>
<tr>
<td>23</td>
<td>TSC TSC2 +</td>
<td>M</td>
<td>3 y</td>
<td>GTC</td>
<td>R F</td>
<td>Spikes at RF</td>
<td>72</td>
<td>12 y 4 m</td>
</tr>
<tr>
<td>24</td>
<td>TSC TSC2 +</td>
<td>F</td>
<td>1 m</td>
<td>Spasm and tonic seizure</td>
<td>L F</td>
<td>Spikes, SW at LF</td>
<td>87</td>
<td>5 m</td>
</tr>
<tr>
<td>25</td>
<td>TSC TSC2 +</td>
<td>F</td>
<td>1 m</td>
<td>Spasm and GTC</td>
<td>L C</td>
<td>Hypsarrhythmia</td>
<td>44</td>
<td>7 m</td>
</tr>
<tr>
<td>26</td>
<td>TSC TSC2 +</td>
<td>M</td>
<td>11 m</td>
<td>Tonic seizure</td>
<td>R F</td>
<td>Spikes at RF</td>
<td>84</td>
<td>1 y 10 m</td>
</tr>
<tr>
<td>27</td>
<td>TSC TSC2 +</td>
<td>F</td>
<td>6 m</td>
<td>GTC</td>
<td>LT</td>
<td>Spikes, slow waves at LT, O</td>
<td>58</td>
<td>2 y 5 m</td>
</tr>
<tr>
<td>28</td>
<td>TSC TSC2 +</td>
<td>F</td>
<td>Nd</td>
<td>Nd</td>
<td>Nd</td>
<td>Nd</td>
<td>Nd</td>
<td>31 y</td>
</tr>
<tr>
<td>29</td>
<td>LGA</td>
<td>M</td>
<td>1 y 7 m</td>
<td>Tonic seizure</td>
<td>R T</td>
<td>Spikes at RT</td>
<td>83</td>
<td>2 y 7 m</td>
</tr>
<tr>
<td>30</td>
<td>LGA</td>
<td>F</td>
<td>13 y</td>
<td>Nd</td>
<td>LT</td>
<td>Sharp at LT</td>
<td>97</td>
<td>18 y 10 m</td>
</tr>
<tr>
<td>31</td>
<td>LGA</td>
<td>M</td>
<td>13 y 8 m</td>
<td>Oral automatism</td>
<td>LT</td>
<td>Sharp, slow waves at LT</td>
<td>78</td>
<td>22 y 3 m</td>
</tr>
</tbody>
</table>

*These scores evaluated at 1 year after resection.
†These scores were evaluated at 1 year after resection. Engel scoring has 4 categories: 1, seizure-free; 2, markedly decreased seizure frequency; 3, moderately decreased seizure frequency; and 4, no change after resection.
FCD, focal cortical dysplasia; TSC, tuberous sclerosis complex; LGA, low-grade astrocytoma; M, male; F, female; m, month (s); y, year (s); GTC, generalized tonic convulsion; CPS, complex partial seizure; Nd, not described; L, left; R, right; O, occipital; P, parietal; F, frontal; T, temporal; SW, spike and slow wave; SB, suppression-burst.
compared with controls. Balloon cells were present in the FCD IIb and TSC lesions, but numbers of balloon cells were excluded because of their variable numbers of GFAP-immunostained and unstained balloon cells in each case and the unknown origin of those cells.

**Statistical Analysis**

Student t test was used for comparison between FCD IIa and FCD IIb in each region. The same test was applied using statistical software (SPSS; SPSS Inc., Chicago, IL) with a significance level of p < 0.05. In addition, regression analyses were performed to compare the ratios in the number of immunopositive cells per astrocyte with various clinical data, including onset age, seizure type, lesion, interval time between onset and surgery, developmental quotient or intelligence quotient, gestational age at birth, and Engel score at 1 year after resection (Table).

**Immunoblotting**

Protein extraction from prepared tissues was carried out according to a previously described procedure (25). The tissues selected for analysis were adjacent to the areas with severe pathologic findings, and 50 μg of the extracted proteins were loaded on each lane. After transfer to a polyvinylidene difluoride membrane, each immunoreacted band was detected using an enhanced chemiluminescence system (Amersham Pharmacia Biotech, Buckinghamshire, UK) according to the manufacturer’s instructions. As a reference, β-actin was detected using a specific antibody (Sigma, St. Louis, MO). The expression levels of detected bands were measured and calculated by ImageQuant TL 7.0 (GE Healthcare, Buckinghamshire, UK) and compared with those of each subgroup.

**RESULTS**

The pathologic classification of FCD cases was done according to recent international criteria (24). There were 5 FCD I, 9 FCD IIa, and 9 FCD IIb patients (Table). The other types of cortical dysplasia, TSC and LGA, were diagnosed by brain magnetic resonance imaging and genetic analysis of TSC1 (hamartin) and/or TSC2 (tuberin) or by having a less than 1% measurement with MiB-1 index (Table).

To evaluate various receptors of astrocytes in epileptogenesis lesions of the brains, emphasis was placed on GFAP-immunopositive cells (Figs. 1, 2). The immunoreactivities for all antibodies appeared to be in the cytosol. These immunostaining patterns in autopsied control sections were the same patterns as those in surgical tissues for all antibodies (Figure, Supplemental Digital Content 2, http://links.lww.com/NEN/A619). Negative immunostaining for all antibodies was performed by omission of the primary antibodies (data not shown).

The ratios of the P2RY1-positive cell number per GFAP-positive cell number (P2RY1/GFAP) were 69.5% ± 19.1% (average ± SD) in FCD I patient samples, 49.9% ± 25.4% in FCD IIa samples, 57.0% ± 22.7% in FCD IIb samples, 66.1% ± 1.2% in TSC samples, 72.0% ± 11.8% in LGA samples, and 0.9% ± 2.8% of control cases (Fig. 3A). The ratios of P2RY2/GFAP in patients samples were 63.3% ± 20.7% in FCD I, 86.2% ± 17.4% in FCD IIa, 99.8% ± 0.4% in FCD IIb, 99.3% ± 1.6% in TSC, 100.0% in LGA, and 1.17% ± 0.5% in control cases (Fig. 3B). The ratios of P2RY4/GFAP...
in patient samples were 80.2% ± 11.6% in FCD I, 91.0% ± 11.3% in FCD IIa, 88.8% ± 21.8% in FCD IIb, 80.2% ± 27.4% in TSC, 90.1% ± 11.7% in LGA, and 3.9% ± 16.7% in control cases (Fig. 3C). The ratios of Kv4.2/GFAP were 57.2% ± 26.5% in FCD I, 40.7% ± 16.2% in FCD IIa, 49.0% ± 23.0% in FCD IIb, 59.3% ± 26.4% in TSC, 44.4% ± 7.5% in LGA, and 9.8% ± 22.5% in control cases (Fig. 3D). The ratios of Kv4.2/GFAP were 80.0% ± 38.0% in FCD I, 65.3% ± 33.7% in FCD IIa, 76.8% ± 30.9% in FCD IIb, 76.1% ± 17.7% in TSC, 98.1% ± 1.1% in LGA, and 9.8% ± 22.5% in control cases (Fig. 3E). The ratios of mGluR1/GFAP were 88.5% ± 9.2% in FCD I, 56.9% ± 30.3% in FCD IIa, 91.7% ± 12.1% in FCD IIb, 78.4% ± 28.3% in TSC, 88.8% ± 9.1% in LGA, and 1.2% ± 1.7% in control cases (Fig. 3F). The ratios of mGluR5/GFAP were 69.4% ± 9.4% in FCD I, 72.0% ± 29.5% in FCD IIa, 69.1% ± 25.0% in FCD IIb, 47.9% ± 30.0% in TSC, 85.1% ± 5.7% in LGA, and 2.4% ± 10.9% in control cases (Fig. 3G).

Compared with control cases, the ratios of P2RY1/GFAP, P2RY2/GFAP, P2RY4/GFAP, Kv4.2/GFAP, Kir4.1/GFAP, mGluR1/GFAP, and mGluR5/GFAP were significantly different among the FCD I, FCD IIa, FCD IIb, TSC, and LGA patient samples (p < 0.001) (Fig. 3). For the ratios of P2RY2/GFAP, there were significant differences between FCD I and FCD IIa, FCD I and FCD IIb, FCD I and TSC, FCD I and LGA, and FCD IIa and FCD IIb (p < 0.05).

The ratios of mGluR1/GFAP were significantly different between FCD I and FCD IIa and between FCD IIa and FCD IIb (p < 0.05), but there were no significant differences between the pathologic subgroups for P2RY1, P2RY4, Kv4.2, Kir4.1, and mGluR5 expression. None of the receptors were found to be expressed by neurons or microglia (Figure, Supplemental Digital Content 3, http://links.lww.com/NEN/A620 and Figure, Supplemental Digital Content 4, http://links.lww.com/NEN/A621). The pathologic gliosis patient samples were not different in any of the ratios versus those of the control samples (Fig. 3).

The immunohistochemical results were reflected in the immunoblotting data (Fig. 4). All receptors were detected at higher levels of expression versus the controls (Figure, Supplemental Digital Content 5, http://links.lww.com/NEN/A622). Moreover, the analysis suggested that, in epileptic foci specifically, there was overexpression of the astrocyte receptors. There were no significant relationships between any receptor–cell marker ratio with specific clinical parameters (Table).

**DISCUSSION**

The number of glial cells in the cerebral cortex is estimated to be more than 3 times the number of neurons (26). Astrocytes have many brain homeostatic functions including modulating synaptic function and plasticity, regulating the perisynaptic environment and contributing to the permeability...
of the blood-brain barrier (3,27). On the other hand, disrupted glial functions can lead to epileptogenesis (8). Abnormal and increased numbers of glia, including astrogliosis and glial tumors, are a prominent feature of epileptic foci in human brains and in the brains of experimental epilepsy animals. One of the mechanisms by which glial cells may promote epilepsy is by increasing neuronal excitability that results in hyperexcitability and hypersynchrony. This may be caused by an imbalance of ions and neurotransmitters as a consequence of glial dysfunction. A few reports have suggested that epileptogenesis may result from dysfunction of astrocyte receptors (3). Alterations of many astrocytic functions in epilepsy, such as of K+-buffering and mGluR-mediated cell signaling, are well known (28,29). Abnormal Ca2+-dependent gliotransmission directly contributes to the excessive neuronal synchronization of seizures. Astrocytes from hyperexcitable networks respond to neuronal signals with massive Ca2+ elevations, thereby generating recurrent neuronal excitation and promoting seizures (10,30). Moreover, astrocyte transmission is necessary for forming the neuron-glia network and performing neuronal functions (31).

We found that most GFAP-positive cells in epilepsy brains overexpressed the astrocytic receptors of P2RY1, P2RY2, P2RY4, Kv4.2, Kir4.1, mGluR1, and mGluR5, although very little of this expression was found in neurons or microglia (Figures, Supplemental Digital Content 3–5). Metabotropic GluR1/GFAP ratios are significantly altered between FCD I, FCD IIa, as well as TSC and LGA. Metabotropic GluR1/GFAP ratios are also significantly altered between FCD I, FCD IIa, and FCD IIb. PG, pathologic gliosis without epilepsy (n = 7); CTL, controls (n = 21); FCD type I, focal cortical dysplasia type I (n = 5); FCD type IIa, focal cortical dysplasia type IIa (n = 9); FCD type IIb, focal cortical dysplasia type IIb (n = 9); TSC, n = 5; LGA (n = 3). * p < 0.05; ** p < 0.01, * p < 0.05 vs. controls.
family, are activated by ATP/ADP. P2RY1, P2RY2, and P2RY4 promote astrocyte proliferation, and P2RY2 interactions with integrins promote astrocyte migration (32). P2RY2 was previously reported to be upregulated in a pathologic astrocyte-proliferating condition (17). Extracellular released ATP, which activates P2 purinergic receptors, can induce the proliferation of astrocytes. Purinergic signaling may, therefore, be a major pathologic mechanism of astrocytes. Interestingly, the ratio of P2RY2/GFAP showed differences between FCD I and other types of FCD, TSC, and LGA, whereas 5 pathologic gliosis patient tissue samples indicated no difference in the ratio of P2RY2/GFAP versus controls. The high ratio of P2RY2/GFAP might, therefore, be characteristic of epileptic foci. In addition, we found a greater P2RY2/GFAP ratio in FCD IIb versus FCD IIa patient samples. This suggests that more severely malformed brains in intractable epilepsy patients have a greater expression of P2RY2. P2RY1 and P2RY2 were recently reported to contribute to neuronal proliferation and migration (7,33). High ratios of P2RY1/GFAP and P2RY2/GFAP may also reflect the extent of malformation of the brains. Indeed, the P2RY2/GFAP ratio grew gradually higher in more severe malformations or glial proliferation (TSC and LGA) (Fig. 3).

These receptors also play important roles in neuron-glia interactions. P2RY2 is expressed in neurons and glial cells and its signaling mediates neuroprotective responses (3,32,34). Astrocytes also release neurotrophic factors that contribute to neuronal survival and sprouting and supply energy substrates to neurons (35). Although P2RY1, P2RY2, and P2RY4 have inhibitory roles in synaptic transmission, postsynaptic P2RY1 and P2RY4 receptors are involved in neuromodulation of transmitter release (36,37). Recently, it has been demonstrated that P2RY1 induction leads to the release of glutamate (38). Our data suggest that increases in the numbers of purinergic receptor–expressing cells may lead to epileptogenesis through the increase of glutamate release and hyperexcitability of neurons.

Metabotropic GluR5 is reported to be expressed in most balloon cells and intensively in astrocytes (39). One recent report indicated that mGluR5 is expressed in premature, but not in mature, astrocytes (40). Our finding that mGluR5-positive astrocytes were identified in epileptic brains may mean that there is immaturity or vulnerability to the environment, as with premature astrocytes. Moreover, mGluR1 is occasionally observed in glial cells (39). Glutamate released from astrocytes can also become a transmitter of neuron-glia communication. Outflow of glutamate from neuronal activity elicits calcium increase in astrocytes through mGluR5 receptors (41). Glutamate from astrocytes has been found to have various effects on neuronal activity through NMDA receptors or mGluR5 receptor, depending on astrocyte calcium levels (42,43), and activation of mGluR1 and mGluR5 in astrocytes results in potassium channel expression (42). Mutations of the human Kir4.1 gene, the product of which is expressed in brain astrocytes, are

FIGURE 4. Immunoblotting of astrocyte receptors in the brains of patients (Pts) with focal cortical dysplasia (FCD), tuberous sclerosis complex (TSC) and low-grade astrocytoma (LGA) (Table). Expression of all receptors is not detected in control (C1, C2) brains, whereas all receptors are expressed at high levels in samples of patient brains. C1 was a 3-month-old who died suddenly with pneumonia (postmortem interval, 3 hours). C2 was 11 years old who died a suddenly with a myocardial infarction (postmortem interval, 2 hours). Patients 3, 5, 8, 11, 15, 18, 25, 24, 29, and 30 in the Table are abbreviated to Pt 3, 5, 8, 11, 15, 18, 25, 24, 29, and 30, respectively.

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Controls</th>
<th>FCD I</th>
<th>FCD IIa</th>
<th>FCD IIb</th>
<th>TSC</th>
<th>LGA</th>
<th>MW (kDa)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2Y1</td>
<td>C1 Pt 3</td>
<td>Pt 8</td>
<td>Pt 15</td>
<td>Pt 25</td>
<td>Pt 30</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>P2Y2</td>
<td>C2 Pt 5</td>
<td>Pt 11</td>
<td>Pt 18</td>
<td>Pt 24</td>
<td>Pt 29</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>P2Y4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>Kir4.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>Kv4.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>mGluR1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>130</td>
<td></td>
</tr>
<tr>
<td>mGluR5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>130</td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>40</td>
<td></td>
</tr>
</tbody>
</table>
associated with epilepsy (44) 16 Kir channels, identified in human genome genes, have been identified in glial cells. Among them, the resting conductance of astrocytes is largely caused by Kir4.1. Loss of Kir4.1 function causes membrane depolarization and breakdown of potassium ion and glutamate homeostasis, which results in seizures (45). The Kir4.1-null epileptic mouse was shown to delay potassium ion clearance after synaptic activation (46). Kir4.1 inactivation in astrocytes impairs extracellular potassium ion and glutamate clearance and produces a seizure phenotype (47). Voltage-gated potassium (Kv) channels are suggested to play an important role in epilepsy. Kv4.2 is expressed in both neurons and astrocytes. Its regulation, which may involve potassium channels, is of interacting proteins, and alterations in the subcellular localization of the channel result in epilepsy (48). The glia-neuron communication is performed with complex transmitters, such as ATP/ADP and glutamate, and through ion channels.

Overexpression of those astrocytic receptors is considered to trigger activation of the related signaling pathways. Astrocytic receptor activation critically contributes to epileptogenesis. Many of the astrocytic functions involving K+-exchanging, along with adenosine- and mGlUR-mediated signaling systems, are altered in epilepsy. Moreover, those functions may trigger the pathogenesis of intractable epilepsy associated with cortical malformations. Thus, astrocytes may become a new target for drug development for epilepsy therapy. In exploring advanced therapeutics, it is important to control the astrocyte receptor–related signaling pathways.

ACKNOWLEDGMENTS

The authors thank Mr. N. Kuninaka and S. Kumagai for their generous assistance with some of the experiments.

REFERENCES

38. Hussel S, Boehm S. Functions of neuronal P2Y receptors. Pflügers Arch 2006;452:538–51

© 2014 American Association of Neuropathologists, Inc.


43. Shigetomi E, Bowser DN, Sofroniew MV, et al. Two forms of astrocyte calcium excitability have distinct effects on NMDA receptor-mediated slow inward currents in pyramidal neurons. *J Neurosci* 2008;28:6659–63


